Cartiac: Comparative Cardiovascular Safety of CAR T Products for Non-Hodgkin’s Lymphoma – a Propensity Score–Matched International Multicenter Study

Post time 1 hour(s) ago

journal：Transplantation and Cellular Therapy

Authors：Mohammad Alhomoud; Ali Abed Al Wahed; Samantha Brown; Uri Greenbaum; Tobias Tix; James Di Palma-Grisi; Elan Baskir; Sarah Samorodnitsky; Parastoo B Dahi; Alessandra Holzem; Linus Kruk; Marion Subklewe; Sandeep Raj; Marina Gomez-Llobell; Sigrun Einarsdottir; Sapir Israeli; Silvia Escribano Serrat; Roi Westreich; Noa Golan Accav; Ori Ben Valid; Ronit Marcus; Avichai Shimoni; Arnon Nagler; Manhal Habib; Jabour Halloun; Dr. Richard J. Lin; Michael Scordo; Gunjan L. Shah; Craig Sauter; Ofrat Beyar- Katz; Gilles Salles; Jae H Park; M. Lia Palomba; Miguel-Angel Perales; Roni Shouval; Abraham Avigdor; Andrew Ip; Kai Rejeski; Jennifer Liu

Published date：2026-2-

DOI：10.1016/j.jtct.2025.12.030

PDF link：https://www.sciencedirect.com/sc ... 666636725016884/pdf

Article link：https://doi.org/10.1016/j.jtct.2025.12.030

Article Source：Elsevier BV。

Remark：

[Elsevier] Cartiac: Comparative Cardiovascular Safety of CAR T Products for Non-Hodgkin’s Lymphoma – a Propensity Score–Matched International Multicenter Study

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Cartiac: Comparative Cardiovascular Safety of CAR T Products for Non-Hodgkin’s Lymphoma – a Propensity Score–Matched International Multicenter Study Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Cartiac: Comparative Cardiovascular Safety of CAR T Products for Non-Hodgkin’s Lymphoma – a Propensity Score–Matched International Multicenter Study